Pharmacyclics, Inc.

Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Institucio Catalana De Recerca I Estudis Avancats

FundaciÓ Privada Institut D'investigaciÓ

OncolÓgica De Vall Hebron

Laura Soucek

Marie-Eve Beaulieu

Toni Jauset González

Daniel Massó-Vallés

Toni Jauset Gonzá#lez

Toni Jauset GONZÁLEZ

The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.

Methods and compositions for the treatment of cancer

The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.

Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ACK inhibitor (e.g., a BTK inhibitor, such as for example an irreversible BTK inhibitor, such as for example, ibrutinib).

Methods of treating fibrosis

Growing community of inventors

Barcelona, Spain

Laura Soucek